智通财经APP获悉，摩根大通首次对CRISPR Therapeutics(CRSP.US)给出“增持”评级，并强调该公司凭借其管线潜力在基因编辑领域占据独特优势。该行分析师Brian Cheng在报告中指出，随着公司投资组合接近多个关键发展拐点，CRISPR Therapeutics值得投资者重新关注，目标价设定为70美元。
作为与福泰制药(VRTX.US)合作销售Casgevy体内基因编辑疗法的瑞士生物科技企业，CRISPR 正通过自身免疫CAR-T候选药物(如CTX112)，为公司提供了更快的市场进入路径。
Brian Cheng特别提到，在制药行业对心血管靶点高度关注的大背景下，公司基于ANGPTL3和Lp(a)候选药物的体内技术，为公司下一增长曲线提供了极具吸引力的机会。
在制药行业对心血管靶点高度关注的大背景下，这些体内技术为公司下一增长曲线提供了极具吸引力的机会。
摩根大通在报告中进一步阐释：“我们相信，CRISPR 通过在自身免疫细胞疗法与体内心血管赛道之间取得平衡，已制定正确战略并储备充足资源，可规避部分基因编辑同行所面临的困境。”
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.